Genmab A/S (GMAB)
37.33
+0.26
(+0.70%)
USD |
NASDAQ |
Oct 12, 14:34
Genmab Cash from Investing (Quarterly) : 2.026M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.026M |
| March 31, 2026 | -9.033M |
| December 31, 2025 | -5.589B |
| September 30, 2025 | -54.15M |
| June 30, 2025 | 25.89M |
| March 31, 2025 | -43.03M |
| December 31, 2024 | 6.474M |
| September 30, 2024 | 28.08M |
| June 30, 2024 | -1.269B |
| March 31, 2024 | -209.77M |
| December 31, 2023 | -62.08M |
| September 30, 2023 | 146.19M |
| June 30, 2023 | -267.03M |
| March 31, 2023 | -1.874M |
| December 31, 2022 | -11.01M |
| September 30, 2022 | -192.67M |
| June 30, 2022 | -82.44M |
| March 31, 2022 | -100.56M |
| December 31, 2021 | -47.45M |
| September 30, 2021 | -261.88M |
| June 30, 2021 | 250.20M |
| March 31, 2021 | -93.77M |
| December 31, 2020 | -115.84M |
| September 30, 2020 | -381.71M |
| June 30, 2020 | 135.02M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.327M |
| December 31, 2019 | -169.35M |
| September 30, 2019 | -7.216M |
| June 30, 2019 | -116.87M |
| March 31, 2019 | -2.059M |
| December 31, 2018 | -90.37M |
| September 30, 2018 | -63.44M |
| June 30, 2018 | -15.80M |
| March 31, 2018 | -112.68M |
| December 31, 2017 | 2.629M |
| September 30, 2017 | 0.1633M |
| June 30, 2017 | -48.81M |
| March 31, 2017 | -55.51M |
| December 31, 2016 | -71.53M |
| September 30, 2016 | -4.463M |
| June 30, 2016 | -39.23M |
| March 31, 2016 | -36.18M |
| December 31, 2015 | -2.519M |
| September 30, 2015 | -6.376M |
| June 30, 2015 | -13.49M |
| March 31, 2015 | -49.54M |
| December 31, 2014 | 13.56M |
| September 30, 2014 | -45.44M |
| June 30, 2014 | -62.03M |
| March 31, 2014 | -87.10M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -1.197B |
| Ascendis Pharma A/S | -3.268M |
| Zealand Pharma A/S | 34.81M |
| Bavarian Nordic A/S | -5.386M |
| Evaxion AS | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 51.04M |
| Cash from Financing (Quarterly) | -74.60M |
| Free Cash Flow | 869.04M |
| Free Cash Flow Per Share (Quarterly) | 0.0779 |
| Free Cash Flow to Equity (Quarterly) | 126.04M |
| Free Cash Flow to Firm (Quarterly) | 160.88M |
| Free Cash Flow Yield | 3.65% |